PL1830833T3 - Połączenie inhibitora transportera glicyny (GLYT1) i środka przeciwpsychotycznego do leczenia objawów schizofrenii jak również sposoby jego wytwarzania oraz zastosowanie - Google Patents
Połączenie inhibitora transportera glicyny (GLYT1) i środka przeciwpsychotycznego do leczenia objawów schizofrenii jak również sposoby jego wytwarzania oraz zastosowanieInfo
- Publication number
- PL1830833T3 PL1830833T3 PL05849954T PL05849954T PL1830833T3 PL 1830833 T3 PL1830833 T3 PL 1830833T3 PL 05849954 T PL05849954 T PL 05849954T PL 05849954 T PL05849954 T PL 05849954T PL 1830833 T3 PL1830833 T3 PL 1830833T3
- Authority
- PL
- Poland
- Prior art keywords
- antipsychotic
- schizophrenia
- symptoms
- glyt1
- treatment
- Prior art date
Links
- 230000000561 anti-psychotic effect Effects 0.000 title abstract 4
- 201000000980 schizophrenia Diseases 0.000 title abstract 3
- 208000024891 symptom Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 title 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940123454 Glucose transporter 1 inhibitor Drugs 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63657504P | 2004-12-16 | 2004-12-16 | |
PCT/US2005/045749 WO2006066121A2 (en) | 2004-12-16 | 2005-12-15 | Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof |
EP05849954A EP1830833B1 (en) | 2004-12-16 | 2005-12-15 | Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1830833T3 true PL1830833T3 (pl) | 2010-06-30 |
Family
ID=36168474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05849954T PL1830833T3 (pl) | 2004-12-16 | 2005-12-15 | Połączenie inhibitora transportera glicyny (GLYT1) i środka przeciwpsychotycznego do leczenia objawów schizofrenii jak również sposoby jego wytwarzania oraz zastosowanie |
Country Status (12)
Country | Link |
---|---|
US (1) | US20060154919A1 (pl) |
EP (1) | EP1830833B1 (pl) |
AT (1) | ATE456366T1 (pl) |
CA (1) | CA2590287A1 (pl) |
CY (1) | CY1110617T1 (pl) |
DE (1) | DE602005019203D1 (pl) |
DK (1) | DK1830833T3 (pl) |
ES (1) | ES2338346T3 (pl) |
PL (1) | PL1830833T3 (pl) |
PT (1) | PT1830833E (pl) |
SI (1) | SI1830833T1 (pl) |
WO (1) | WO2006066121A2 (pl) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008032056A2 (en) * | 2006-09-16 | 2008-03-20 | Genophrenix Limited | Dopamine receptor interacting proteins as markers for disease |
WO2008040669A2 (en) * | 2006-10-02 | 2008-04-10 | Janssen Pharmaceutica N.V. | Novel intermediates for the preparation of a glyt1 inhibitor |
JP2018530593A (ja) * | 2015-10-16 | 2018-10-18 | ノースウェスタン ユニバーシティ | 統合失調症、双極性障害、認知障害及び大うつ病性障害の治療のための非定型的抗精神病薬ならびにnmda調節剤の医薬品の組み合わせ |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187171A (en) * | 1989-01-09 | 1993-02-16 | G. D. Searle & Co. | Use of a glycine b partial agonist as an antipsychotic |
EP0871440B1 (en) * | 1995-12-07 | 2006-03-22 | Daniel C. Javitt | Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists |
EP1844769A3 (en) * | 1998-04-14 | 2010-02-10 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
US6476208B1 (en) * | 1998-10-13 | 2002-11-05 | Genset | Schizophrenia associated genes, proteins and biallelic markers |
US6426364B1 (en) * | 1999-11-01 | 2002-07-30 | Nps Allelix Corp. | Diaryl-enynes |
US6335681B1 (en) * | 2001-02-08 | 2002-01-01 | Teofilo Ontiveros | Cruise control alert |
BR0207307A (pt) * | 2001-02-16 | 2004-08-17 | Allelix Neuroscience Inc | Inibidores de glyt-1 |
GB0314479D0 (en) * | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Compounds |
CN1878551A (zh) * | 2003-11-12 | 2006-12-13 | 默克公司 | 4-苯基哌啶磺酰基甘氨酸转运体抑制剂 |
WO2005058885A2 (en) * | 2003-12-18 | 2005-06-30 | Glaxo Group Limited | Piperidine derivatives and their use as glycine transporter inhibitors |
WO2005058317A1 (en) * | 2003-12-18 | 2005-06-30 | Glaxo Group Limited | Glycine transporter-1 inhibirors |
WO2006000222A2 (en) * | 2004-06-24 | 2006-01-05 | H. Lundbeck A/S | The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia |
-
2005
- 2005-12-15 AT AT05849954T patent/ATE456366T1/de active
- 2005-12-15 CA CA002590287A patent/CA2590287A1/en not_active Abandoned
- 2005-12-15 US US11/304,175 patent/US20060154919A1/en not_active Abandoned
- 2005-12-15 EP EP05849954A patent/EP1830833B1/en active Active
- 2005-12-15 ES ES05849954T patent/ES2338346T3/es active Active
- 2005-12-15 PL PL05849954T patent/PL1830833T3/pl unknown
- 2005-12-15 PT PT05849954T patent/PT1830833E/pt unknown
- 2005-12-15 WO PCT/US2005/045749 patent/WO2006066121A2/en active Application Filing
- 2005-12-15 SI SI200530955T patent/SI1830833T1/sl unknown
- 2005-12-15 DK DK05849954.2T patent/DK1830833T3/da active
- 2005-12-15 DE DE602005019203T patent/DE602005019203D1/de active Active
-
2010
- 2010-04-14 CY CY20101100335T patent/CY1110617T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006066121A3 (en) | 2006-08-10 |
ES2338346T3 (es) | 2010-05-06 |
DE602005019203D1 (de) | 2010-03-18 |
SI1830833T1 (sl) | 2010-05-31 |
CA2590287A1 (en) | 2006-06-22 |
WO2006066121A2 (en) | 2006-06-22 |
EP1830833B1 (en) | 2010-01-27 |
EP1830833A2 (en) | 2007-09-12 |
US20060154919A1 (en) | 2006-07-13 |
ATE456366T1 (de) | 2010-02-15 |
CY1110617T1 (el) | 2015-04-29 |
DK1830833T3 (da) | 2010-05-17 |
PT1830833E (pt) | 2010-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2383271E (pt) | Aminoquinolonas como inibidores de gsk-3 | |
IL162828A0 (en) | Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection | |
WO2006068729A3 (en) | Methods and compositions for enhancing iron absorption | |
EA200800755A1 (ru) | Ikk ингибиторы, предназначенные для лечения эндометриоза | |
SG170044A1 (en) | Ocular allergy treatments | |
WO2005117943A3 (en) | Biomarkers for monitoring inhibition of impdh pathway | |
UA88166C2 (ru) | Применение пептидных соединений для лечения эссенцильного дрожания и других синдромов дрожания | |
TW200716145A (en) | Use of LGG in the manufacture of a medicament for the prevention or treatment of respiratory allergies | |
ECSP055844A (es) | Nuevos compuestos triciclicos | |
WO2004000293A3 (fr) | Utilisation de la taurine ou de derives pour le traitement de l'alopecie | |
IL192181A0 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
EA200800766A1 (ru) | Ингибиторы pi3k для лечения эндометриоза | |
WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
TNSN07240A1 (en) | Compounds for flaviviridae treatment | |
HK1162502A1 (en) | Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3 | |
WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
WO2004028548A3 (en) | Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents | |
WO2006084153A3 (en) | Methods and materials with trans-clomiphene for the treatment of male infertility | |
WO2009130615A3 (de) | Verwendung von deuteriumoxid als elastase-inhibitor | |
PL1830833T3 (pl) | Połączenie inhibitora transportera glicyny (GLYT1) i środka przeciwpsychotycznego do leczenia objawów schizofrenii jak również sposoby jego wytwarzania oraz zastosowanie | |
WO2005020970A3 (en) | Protease inhibitor compositions for prevention and treatment of skin conditions | |
WO2008050133A3 (en) | Inhibition of beta-amyloid aggregation | |
UA96736C2 (ru) | Ингибиторы pi3k для лечения эндометриоза | |
WO2009067225A3 (en) | Boceprevir derivatives for the treatment of hcv infections | |
WO2007097980A3 (en) | Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy |